Physician profile
Beau Kalmes
NPI 1083062475
$896.13
in general payments reported to CMS, 2019-2025
23 companies · $144 in 2025
The $144 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $31.14 · 2021: $63.44 · 2022: $25.21 · 2023: $199 · 2024: $129 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $142.48 | 2019-2020 | |
| Bioventus LLC | $71.03 | 2022-2025 | Exogen Ultrasound Bone Healing System, Durolane |
| Nevro Corp. | $63.44 | 2021 | |
| Mallinckrodt Enterprises LLC | $56.42 | 2019 | |
| Celgene Corporation | $47.80 | 2019 | |
| Exact Sciences Corporation | $46.91 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $44.73 | 2023 | Mounjaro |
| Vertex Pharmaceuticals Incorporated | $42.21 | 2025 | |
| Orthofix Medical, INC. | $42.07 | 2023-2025 | Physio-Stim |
| Novo Nordisk INC | $41.41 | 2023-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $39.85 | 2023-2024 | Trintellix |
| Ucb, INC. | $37.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.45 | 2019 | |
| Amgen INC. | $34.12 | 2023 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.40 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $22.58 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $20.95 | 2024 | Airsupra |
| Pfizer INC. | $18.61 | 2023 | |
| Phathom Pharmaceuticals, INC. | $18.20 | 2024 | Voquezna |
| Verity Pharmaceuticals INC. | $17.20 | 2024 | Tlando |
| Philips North America LLC | $16.47 | 2020 | |
| Boston Scientific Corporation | $14.78 | 2025 | Wavewriter Alpha Prime 16 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$15,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beau Kalmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.